AstraZeneca Annual Report and Form 20-F Information 2011

Index2011 performance summary 23Accounting policies 146, 194Acquisitions and disposals 170Annual general meeting 112, 208Aptium Oncology 22Articles of association 206, 208Astra Tech 22Audit Committee 107Biologics 16, 18, 19Board 99Branches 111Business background and results overview 83Capitalisation 90Cardiovascular 58Cash and cash equivalents 148, 160Chairman’s statement 6Chief Executive Officer’s review 8Commitments and contingent liabilities 181Company history 203, 208Competition 15, 133Compliance and Group Internal Audit 43, 110Consolidated statement of cash flows 145Consolidated statement of changes in equity 144Consolidated statement of comprehensive income 142Consolidated statement of financial position 143Corporate Responsibilitysee Responsible BusinessDirectors’ interest in shares 125Directors’ remuneration 113Directors’ responsibility statement 140Dividends 6, 90, 170, 205Earnings per ordinary share 4, 154Emerging markets 16, 36, 77, 80, 132, 209Employee costs and share plans for employees 176Environmental sustainability 53Established markets 16, 36, 77, 78, 209Ethics 50, 51Finance income and expense 152Financial instruments 148, 161Financial position 2010 93Financial position 2011 88Financial risk management 93, 171Financial summary 1Gastrointestinal 62Glossary 209Goodwill 88, 93, 96, 147, 157Group financial record 198Group financial statements 139Growth drivers 15Independent auditor’s report 141, 192Infection 64Inflammationsee Respiratory & InflammationIntangible assets 88, 93, 95, 96, 147, 158Intellectual Property 34, 131, 132, 133Interest-bearing loans and borrowings 148, 161, 173, 195Inventories 148, 160Key performance indicators 23Leases 148, 190Litigation 96, 133, 136, 149, 183, 184, 194, 197Managing risk 129Market definitions 209Medicines 3, 4, 10, 32, 35, 56Neuroscience 67Nomination and Governance Committee 105, 106, 109Oncology 70Operating profit 1, 4, 23, 85, 91, 151Operational overview 5Other investments 148, 160Outsourcing 21, 135Patentssee Intellectual PropertyPatient safety 53People 19, 21, 25, 40, 176Pipeline 5, 19, 21, 24, 31, 32, 57, 130, 199Political donations 112Portfolio Investment Board (PIB) 110Post-retirement benefits 96, 138, 165Pricing 18, 37Principal risks and uncertainties 129Product revenue information 150Property, plant and equipment 148, 156Provisions for liabilities and charges 88, 93, 164Regulatory requirements 17Related party transactions 205Relations with shareholders 106Remuneration Committee 113Research and Development 16, 30, 147, 151Reserves 169Respiratory & Inflammation 73Responsible Business 47Rest of World 79, 209Restructuring 22, 151Results of operations 2010 91Results of operations 2011 85Safety, health and wellbeing 54Sales and Marketing 36Sales by therapy area 56Science Committee 109Segment information 154Senior Executive Team (SET) 102, 110Share capital 170, 196, 203Share repurchase 90, 111, 170, 196Statutory and other information 190Strategy 19Subsidiaries 191Supply and Manufacturing 38Taxation 89, 93, 97, 138, 147, 152, 189Taxation information for shareholders 206Trade and other payables 88, 93, 148, 164Trade and other receivables 88, 93, 148, 160Trade marksinside back coverTransactions with directors 124UK corporate governance 103UK Corporate Governance Code 103US 78, 209US corporate governance 109World pharmaceutical markets 16212 IndexAstraZeneca Annual Report and Form 20-F Information 2011